Tacrolimus News and Research

RSS

Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.

New immunosuppressive regimens may improve outcomes for kidney transplant patients

Preliminary results from a $5.2 million clinical trial led by University of Cincinnati researchers show that the immunosuppressive drug belatacept can help safely and effectively treat kidney transplant patients without the negative long-term side effects of traditional immunosuppressive regimens, the study's leaders announced this week.

6 Jun 2019

Scientists discover how protein molecules regulate formation of myelin sheaths

According to the Deutsche Multiple Sklerose Gesellschaft, around 200,000 people in Germany suffer from multiple sclerosis- a serious neurological condition that has no known cure.

8 May 2018

Scientists develop more cost-effective way to culture stem cells

Human pluripotent stem cells can infinitely self-renew and develop into all major cell types in the body, making them important for organ repair and replacement. But culturing them in large quantities can be expensive. Now, scientists at Japan's Kyoto University, with colleagues in India and Iran, have developed a more cost-effective culture by using a new combination of chemical compounds.

5 Mar 2018

Early and targeted treatment of dnDSA preserves allograft function

Development of de novo donor-specific antibodies (dnDSA) is known to cause graft failure. Therefore, a protocol aimed at prospective monitoring and treating dnDSA--before it can cause graft damage--was developed for kidney transplant recipients at Children National Health System.

5 Feb 2018

Calcium controls use of glucose by T cells to multiply and battle against infection, study finds

A calcium signal controls whether immune cells can use the nutrients needed to fuel their multiplication into a cellular army designed to fight invading viruses.

11 Oct 2017

Liver transplant patients who take new anti-rejection drug gain less weight, study finds

Researchers have discovered that a new anti-rejection drug that is gentler on the kidneys after liver transplant also reduces weight gain, which is common after surgery and can lead to serious complications for transplant patients.

3 May 2017

New BSR guideline provides evidence-based recommendations for clinicians prescribing non-biologic DMARDs

This latest guidance sets out evidence based recommendations for clinicians prescribing synthetic, non-biologic, anti-rheumatic drugs to tackle multisystem rheumatic conditions.

1 Mar 2017

Results of high-impact clinical trials could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL.

21 Nov 2016

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Researchers from Massachusetts Eye and Ear/Harvard Medical School have conducted a clinical trial comparing the safety and efficacy of topical tacrolimus, an immunosuppressive therapy, and topical methylprednisolone, a steroid medication, in patients with ocular graft-versus-host-disease (GVHD) -- a complication associated with allogeneic bone marrow transplants in which the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface.

16 Apr 2016

Phenotypic personalized medicine can identify a person's optimal drug, dose combinations

For decades, doctors and scientists have predicted that personalized medicine — tailoring drug doses and combinations to people's specific diseases and body chemistry — would be the future of health care.

7 Apr 2016

Biomarkers may provide novel approaches to monitoring immunosuppressive therapy in organ transplant patients

Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients--with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

17 Mar 2016

Many kidney transplant patients may benefit from lower-than-standard dose of CNIs

The kidney is the most commonly transplanted organ in the United States, with more than 17,000 transplants performed each year. Following kidney transplant, patients are routinely placed on a regimen of immunosuppressant medications to prevent organ rejection, which often includes calcineurin inhibitors (CNIs) as the backbone medication of this regimen.

16 Mar 2016

Anti-aging Glycopeptide can improve efficacy of cell transplant treatments for diabetes patients

An antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of cell transplant treatments for diabetes patients--a procedure that transplants insulin producing islets to render them insulin independent for periods of time.

18 Dec 2015

Study suggests combination of MMF and CNIs can protect against rare lymphoma

16 Oct 2015

Researchers link organ transplant drug to rise in rare lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil (MMF) to an increased risk of central nervous system (CNS) lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, called calcineurin inhibitors (CNIs), given alone or in combination with MMF, appears to protect transplant patients against this rare form of lymphoma.

15 Oct 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015.

14 Aug 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015